231 related articles for article (PubMed ID: 32086972)
1. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.
Dubey D; David WS; Reynolds KL; Chute DF; Clement NF; Cohen JV; Lawrence DP; Mooradian MJ; Sullivan RJ; Guidon AC
Ann Neurol; 2020 May; 87(5):659-669. PubMed ID: 32086972
[TBL] [Abstract][Full Text] [Related]
2. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
Balaji A; Zhang J; Wills B; Marrone KA; Elmariah H; Yarchoan M; Zimmerman JW; Hajjir K; Venkatraman D; Armstrong DK; Laheru DA; Mehra R; Ho WJ; Reuss JE; Heng J; Vellanki P; Donehower RC; Holdhoff M; Naidoo J
J Oncol Pract; 2019 Sep; 15(9):e825-e834. PubMed ID: 31386608
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
7. Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.
Patil PD; Fernandez AP; Velcheti V; Tarhini A; Funchain P; Rini B; Khasawneh M; Pennell NA
Oncologist; 2019 Jan; 24(1):4-8. PubMed ID: 30355774
[TBL] [Abstract][Full Text] [Related]
8. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
10. A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
Naidoo J; Zhang J; Lipson EJ; Forde PM; Suresh K; Moseley KF; Mehta S; Kwatra SG; Parian AM; Kim AK; Probasco JC; Rouf R; Thorne JE; Shanbhag S; Riemer J; Shah AA; Pardoll DM; Bingham CO; Brahmer JR; Cappelli LC
J Natl Compr Canc Netw; 2019 Jun; 17(6):712-720. PubMed ID: 31200355
[TBL] [Abstract][Full Text] [Related]
11. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
12. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
15. Management of immune related adverse events induced by immune checkpoint inhibition.
Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
17. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Fahey CC; Gracie TJ; Johnson DB
Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
[TBL] [Abstract][Full Text] [Related]
19. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Xu M; Nie Y; Yang Y; Lu YT; Su Q
Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
[TBL] [Abstract][Full Text] [Related]
20. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]